December 1999
CMAJ: Canadian Medical Association Journal;11/30/99 Supplement, Vol. 161, pS21
Academic Journal
The article focuses on the role of immunotherapy in the management of asthma. The efficacy of immunotherapy in treating asthma remains controversial. The results of the studies also vary considerably. Information on the studies conducted to determine the efficacy of immunotherapy is provided. The factors to consider in using immunotherapy for asthma are also mentioned.


Related Articles

  • Safety of Sublingual Immunotherapy in Children with Asthma. Pajno, Giovanni B.; Peroni, Diego G.; Vita, Daniela; Pietrobelli, Angelo; Parmiani, Silvano; Boner, Attilio L. // Pediatric Drugs;2003, Vol. 5 Issue 11, p777 

    Introduction: Two previously published studies on sublingual immunotherapy (SLIT) did not report any serious adverse event associated with the local therapy; however, adverse events were observed in greatly variable percentages. The aim of the study was to evaluate the tolerability profile of...

  • Addition of peak flow monitoring to symptom monitoring did not improve healthcare visits, quality of life, or lung function in older adults with moderate-to-severe asthma. Buist, A. S.; Vollmer, W. M.; Wilson, S. R. // Evidence Based Medicine;Apr2007, Vol. 12 Issue 2, p49 

    The article presents a study which investigates whether the addition of peak flow monitoring to symptom monitoring is effective in treating older adults with moderate-to-severe asthma (MTSA). The study let the patients attend small group sessions including a review of asthma diaries. The result...

  • Commentary. Peters, Jay I. // Evidence Based Medicine;Apr2007, Vol. 12 Issue 2, p49 

    The author comments on a study which investigates whether the addition of peak flow monitoring to symptom monitoring is effective in treating older adults with moderate-to-severe asthma (MTSA). It is asserted that despite the strength of data supporting action plans in the study, limited data...

  • Unanswered clinical questions and speculation about the role of anti-immunoglobulin E in atopic and nonatopic disease. Lanier, Bob // Allergy & Asthma Proceedings;Mar/Apr2006 Supplement, Vol. 27, pS37 

    As clinical experience with omalizumab increases, questions arise from clinicians that are not answered in the product insert or clinical reports. How does this drug really work? There surely must be more than the simple reduction of free IgE which, in and of itself, causes no disease. Can...

  • Sublingual Immunotherapy and Asthma. Saporta, Diego // Townsend Letter;Oct2010, Issue 327, p44 

    The article examines the results of a study on 10 allergic rhinitis (AR)-asthmatic patients with sublingual immunotherapy (SLIT). The researchers counseled the patients about risks and benefits of the therapy and scored symptoms pretreatment and periodically during treatment. Findings affirmed...

  • Sublingual immunotherapy in asthma and rhinoconjunctivitis; systematic review of paediatric literature. Sopo, S. Miceli; Macchiaiolo, M.; Zorzi, G.; Tripodi, S. // Archives of Disease in Childhood;Jul2004, Vol. 89 Issue 7, p620 

    Aims: To evaluate the clinical efficacy of sublingual immunotherapy (SLIT) in respiratory allergy in children. Methods: A systematic literature review was conducted. The search was focused on all the double blind (and double dummy if necessary) studies. Search strategy: Medline, Embase, Cochrane...

  • The new contract: asthma. Levy, Mark // GP: General Practitioner;10/20/2003, p79 

    The inclusion of asthma and COPD in the new general medicine services contract is to be welcomed. Practices providing well-organized asthma services should be able to achieve the necessary points to qualify for payment. A significant proportion of patients who die from asthma have no obvious...

  • Saving asthmatics.  // British Medical Journal;6/9/1979, Vol. 1 Issue 6177, p1520 

    Focuses on the means of controlling the number of deaths from asthma. Need for the education of patients; Improvement of medical supervision; Importance of prompt recognition and treatment.

  • Salmeterol/fluticasone propionate saves in chronic asthma.  // PharmacoEconomics & Outcomes News;7/28/2007, Issue 533, p5 

    The article reports on a research on the use of salmeterol/fluticasone propionate as treatment for asthma. According to the researchers, switching to salmeterol/ fluticasone propionate is generally cost-effective in adults and children. In the study, a model which examined the effect on...


Read the Article


Sign out of this library

Other Topics